Background {#Sec1}
==========

Colorectal cancer (CRC) is the third most common cancer worldwide, with an estimated 1.4 million new cases in 2012 \[[@CR1]\]. In China, CRC had an estimated 376,300 cases, which made it the fifth most common cancer in 2015 \[[@CR2]\]. The most common causes of cancer treatment failure are relapse and metastasis. This may be related to an oncogene called metastasis-associated in colon cancer 1 (MACC1). In 2009, MACC1 was first found in colon cancer cell lines \[[@CR3]\]. MACC1 is reported to combine with the mesenchymal-epithelial transition (MET) gene promoter and so participate in the hepatocyte growth factor/mesenchymal-epithelial transition (HGF/MET) signaling pathway \[[@CR3], [@CR4]\]. MACC1 is also reported to not only promote tumor cell proliferation, invasion, and dissemination by inducing epithelial-mesenchymal transition (EMT) in vitro \[[@CR5], [@CR6]\] but also to induce tumor cell growth, invasion, and metastasis in vivo \[[@CR3], [@CR7]\]. It has been demonstrated that MACC1 should be defined as a prognostic and metastatic biomarker for various cancers \[[@CR8]\].

Many more studies have ascribed tumor metastasis and recurrence to a subpopulation of tumor cells defined as cancer stem cells (CSCs, also called tumor-initiating cells). CSCs have the characteristics of self-renewal, proliferation, invasiveness, and metastasis. They are responsible for cancer initiation and natural resistance to therapy \[[@CR8]--[@CR12]\]. CD44 is not only a common biomarker of CSCs in cancers, such as colorectal cancer, lung cancer, and glioblastoma \[[@CR13]--[@CR15]\], but also a receptor of hyaluronan. CD44 levels are correlated with cell-to-extracellular matrix (ECM) adhesion, cell growth, and angiogenesis \[[@CR16], [@CR17]\].

It has been demonstrated that cancer cells can invade and metastasize after they lose epithelial features and gain a mesenchymal phenotype, which is called the epithelial-mesenchymal transition (EMT) \[[@CR18], [@CR19]\]. Twist1, which belongs to the highly conservative basic helix-loop-helix family, is a transcription factor. Twist1 is a pivotal regulator of EMT and reported to promote N-cadherin synthesis and inhibit E-cadherin expression \[[@CR20], [@CR21]\], thus causing profound morphological changes in tumor cells and expression of cell-matrix adhesion genes to induce tumor cell mobility and migration \[[@CR22]\].

KiSS-1, which was originally identified in non-metastatic melanoma by analysis of subtractive hybridization, is widely considered a critical cancer metastasis suppressor gene \[[@CR11], [@CR23]\]. The KiSS-1 gene, which encodes a 145-amino-acid protein, can bind to the G protein-coupled receptor 54 (GPR54, also called KiSS-1R). KiSS-1 can control cell-cell adhesion by promoting E-cadherin expression and cell-matrix adhesion and cytoskeleton remodeling through inhibition of MMP expression \[[@CR11], [@CR24], [@CR25]\]. KiSS-1 expression is also reported to suppress the metastatic potential of tumor cells but not tumorigenicity \[[@CR25], [@CR26]\]. Further studies have demonstrated that downregulation of KiSS-1 may be involved in the process of tumor invasiveness and metastasis \[[@CR11], [@CR25], [@CR26]\].

The purpose of the current study is to assess the expression of MACC1, CD44, Twist1, and KiSS-1 in the colonic adenocarcinoma (CAC) tissues of patients and their associations between pathological characteristics and prognosis of patients with CAC. Immunohistochemistry was used to evaluate the expression of MACC1, CD44, Twist1, and KiSS-1 in CAC tissues and the corresponding adjacent normal colon mucosa tissues of patients with CAC.

Methods {#Sec2}
=======

Patients and tissue specimens {#Sec3}
-----------------------------

We collected the records of 212 patients (median age: 56.6 years; and range: 29--78 years) with CAC (rectal adenocarcinomas were excluded) diagnosed at the Department of Pathology at our hospital from January 2010 to December 2011. Because all outcomes had already taken place before the study began, it is retrospective. Patients who had any history of anti-cancer therapy were excluded. All patients with CAC provided written, extensively informed consent for their specimens to be used (including in hospital and out hospital). The study was carried out in accordance with the Declaration of Helsinki guidelines and approved by the Bengbu Medical College ethics committee (No. BBMCEC2016024). We collected patient data including complete clinicopathological, demographic, and follow-up data (follow-up at 3-month intervals through mobile phone or social applications). Overall survival (OS) time was computed from the date of radical surgery to date of death or to December 2016 (their mean OS: 53.3 months; and range: 22--72 months). TNM stages and LNM stages were calculated in accordance with the 8th edition of the guidelines issued by the American Joint Committee on Cancer (AJCC). Tumor grades were calculated in accordance with the standards issued by the World Health Organization (WHO). Specific clinicopathological characteristics are shown in Table [1](#Tab1){ref-type="table"}.Table 1Patients characteristicsPatients characteristicsFrequency (*n*)Percentage (%)Gender Male14267.0 Female7033.0Ages ≤ 6013463.2 \> 607836.8Size ≤ 2.0 cm3315.6 \> 2.0 cm, ≤5.0 cm11051.9 \> 5.0 cm6932.5Location Ascending4219.8 Transverse6430.2 Descending3315.6 Sigmoid7334.4Gross type Ulcerative6530.7 Infiltrating4621.7 Polypoid6832.1 Colloid3315.6Invasion Submucosa3617.0 Muscularis6430.2 Subserosa^a^10147.6 Visceral peritoneum^b^115.2Grade Well3215.1 Moderate13563.7 Poor4521.2Lymph node metastasis stages N013664.2 N17033.0 N262.8TNM stage I6932.5 II6731.6 III7635.8^a^The tumor has grown through the muscularis propria and into the subserosa, which is thin layer of connective tissue beneath the outer layer of some parts of the large intestine, or it has grown into tissues surrounding the colon. ^b^ The tumor has grown into the surface of the visceral peritoneum, which means it has grown through all layers of the colon, or the tumor has grown into or has attached to other organs or structures

Immunohistochemistry {#Sec4}
--------------------

All tissues were fixed in 10% buffered formalin solution and then embedded in paraffin. All tissues were then cut into 4-μm-thick sections. Immunostaining was conducted using the Elivision™ Plus method, and the procedure was performed in accordance with the kit instructions. Samples were deparaffinized using routine methods and dehydrated using xylene and alcohol. Methanol containing 3% H~2~O~2~ solution was used for blocking endogenous peroxidase activity, and citrate buffer was used to repair antigen. Goat serum was used for blocking. MACC1 (rabbit polyclonal antibody, Santa Cruz Biotechnology, US), CD44 (mouse monoclonal antibody, Abcam, US), Twist1 (mouse monoclonal antibody, Abcam, US), and KiSS-1 (mouse monoclonal antibody, Santa Cruz Biotechnology, US) primary antibodies were added, and then all sections were incubated overnight at 4 °C. Then enhancer (reagent A) and reagent B were added. The images were allowed to develop in diaminobenzidine (DAB) substrate. Finally, all sections were re-dyed with hematoxylin and mounted with gum.

Assessment of immunostaining {#Sec5}
----------------------------

Ten randomly selected high-power-field (HPF) fields of every CAC section were selected to forestall any intratumoral heterogeneity of marker expression. In accordance with percentage of positive cells and positive intensity, immunostaining results were multiplied using intensity scores (0 points means none; 1 point means weak staining; 2 points means moderate staining; 3 point means strong staining) and percentage scores (1 point is positive cells ≤10%; 2 points is 10% \< positive cells ≤50%; 3 points is 50% \< positive cells ≤75%; 4 points is positive cells \> 75%) which ranged from 0 to 12 \[[@CR8], [@CR11]\]. Here \> 2 points was considered indicative of positive expression. For slices positive for all of biomarkers, the average score of all sections was taken.

Statistical analysis {#Sec6}
--------------------

All data were analyzed using SPSS 19.0 software (Chicago, IL, US). Countable data were subjected to the Chi-square test for comparisons between two groups. Multivariate logistic regression analysis was performed to establish the relative factors for metastasis. Univariate OS analysis was carried out using the Kaplan-Meier method with log-rank test. Multivariate OS analysis was carried out using Cox regression model test. *P* \< 0.05 was considered indicative of statistically significant differences.

Results {#Sec7}
=======

Associations between MACC1, CD44, Twist1, and KiSS-1 in cancer tissues of patients and clinicopathological characteristics {#Sec8}
--------------------------------------------------------------------------------------------------------------------------

As shown in Fig. [1a, b](#Fig1){ref-type="fig"}, MACC1-positive expression was mainly confined to the cytoplasm. The positive expression of MACC1 in the CAC specimens (61.3%, 130/212) was significantly higher than in the normal colon mucosa specimens (7.1%, 15/212; *P* \< 0.001). The immunostaining results indicated that positive expression of MACC1 in CAC was positively correlated with invasion, tumor differentiation, LNM stages, and TNM stages (Table [2](#Tab2){ref-type="table"}).Fig. 1Immunostaining for MACC1, CD44, Twist1, and KiSS-1 in colon adenocarcinoma and control tissue. **a**: Negative MACC1 in the control tissue (400 magnification); **b**: Positive MACC1 in the CAC tissue (400 magnification); **c**:Negative CD44 in the control tissues (400 magnification); **d**: Positive CD44 in the membrane and cytoplasm of cancer cells (400 magnification); **e**: Negative Twist1 in the control tissue (400 magnification); **f**: Positive Twist1 in the cytoplasm and nuclei of the cancer cells (100 magnification); **g**: Positive KiSS-1 in the cytoplasm of control cells (400 magnification); **h**: Negative KiSS-1 in the cancer tissue (400 magnification)Table 2The correlation between MACC1, or CD44, or Twist1, or KiSS-1 and clinicopathological characteristics in colon adenocarcinomaVariableMACC1*P*CD44PTwist1PKiSS-1*P*NegativePositiveNegativePositiveNegative PositiveNegativePositiveGender0.2390.9290.7830.564 Male5191647850928755 Female3139323826444030Age (years)0.2630.9270.7750.833 ≤604886617349858153 \> 603444354327514632Size (cm)0.0810.3750.085\< 0.001 ≤2.01023141910231617 \> 2.0, ≤5.03872466434768030 \> 5.03435363332373138Location0.8630.1560.5070.526 Ascending1725212113292121 Transverse2242253922423925 Descending1320112210232112 Sigmoid3043393431424627Gross type0.0560.4060.0020.929 Ulcerative2738353031343728 Infiltrating103620266402817 Polypoid2939284025434127 Colloid1617132014192112Invasion0.0350.0400.0020.003 Submucosa2016211519171323 Muscularis1945293530343826 Subserosa4160455625766635 Visceral peritoneum2911029101Grade0.0320.024\< 0.0010.745 Well1814201219131814 Moderate5283627353828055 Poor123314314412916LNM stages\< 0.001\< 0.001\< 0.001\< 0.001 N07165855164726076 N1115911591258619 N206060660TNM stage\< 0.001\< 0.001\< 0.001\< 0.001 I3732472240292346 II3433382924433730 III116511651264679

As shown in Fig. [1c, d](#Fig1){ref-type="fig"}, CD44 positive expression was mainly confined to the cell membrane and cytoplasm. Similar to MACC1, the positive expression of CD44-positive expression in CAC tissues (54.7%, 116/212) was significantly greater than in the normal colon mucosa tissues (16.5%, 35/212; *P* \< 0.001). The results also demonstrated that positive expression of CD44 in CAC was positively correlated with invasion, tumor differentiation, LNM stages, and TNM stages (Table [2](#Tab2){ref-type="table"}).

As shown in Fig. [1e, f](#Fig1){ref-type="fig"}, Twist1 expression was mainly confined to the cytoplasm and nuclei. The expression of Twist1 in CAC tissues (64.2%, 136/212) was significantly greater than in the normal colon mucosa tissues (9.4%, 20/212; *P* \< 0.001). The results also showed that Twist1 expression in CAC was significantly closely associated with tumor differentiation, gross type, invasion, LNM stages, and TNM stages (Table [2](#Tab2){ref-type="table"}).

As shown in Fig. [1g, h](#Fig1){ref-type="fig"}, KiSS-1-positive expression was mainly confined to the cytoplasm. The positive expression of KiSS-1 in CAC tissues (40.1%, 82/212) was significantly lower than in the normal colon mucosa tissues (94.3%, 200/212; *P* \< 0.001). The results indicated that positive expression of KiSS-1 was inversely correlated with tumor size, invasion, LNM stages, and TNM stages (Table [2](#Tab2){ref-type="table"}).

Associations among MACC1, CD44, Twist1, and KiSS-1 in CAC {#Sec9}
---------------------------------------------------------

The association between KiSS-1 expression and MACC1, CD44, and Twist1 expression was found to be negative (*r* = − 0.437; *r* = − 0.397; *r* = − 0.251; respectively; *P* \< 0.001) (Table [3](#Tab3){ref-type="table"}). The association between MACC1 expression and CD44 expression and Twist1 expression was found to be positive (*r* = 0.270, *P* \< 0.001; *r* = 0.315, *P* \< 0.001). The association between CD44 expression and Twist1 expression was found to be positive (*r* = 0.150, *P* = 0.029) (Table [3](#Tab3){ref-type="table"}).Table 3Correlation among MACC1, CD44, Twist1 and KiSS-1 in CACVariableMACC1r*P*CD44r*P*KiSS-1r*P*NegativePositiveNegativePositiveNegativePositiveMACC10.270\< 0.001^a^−0.437\< 0.001^b^ Negative51312755 Positive458510030CD440.270\< 0.001^a^−0.397\< 0.001^b^ Negative51453759 Positive31859026Twist10.315\< 0.001^a^0.1500.029^a^−0.251\< 0.001^b^ Negative453142343343 Positive379954829442^a^positive correlation, ^b^negative correlation

Metastasis {#Sec10}
----------

Univariate metastasis analysis indicated that invasion was positively correlated with LNM stages (*P* \< 0.05). Multivariate metastasis logistic analysis suggested that overexpression of MACC1, CD44, Twist1, and down-regulation of KiSS-1 and invasion were both significantly closely associated with LNM (Table [4](#Tab4){ref-type="table"}).Table 4Univariate analysis and multivariate analysis of factors affecting lymph node metastasisVariablesCategoriesUnivariate analysisMultivariate analysis*P*HR95% CI*P*InvasionSubserosa/ Visceral peritoneum^a^\< 0.00112.3361.264-120.4270.031MACC1Negative/Positive\< 0.0012.9561.222--7.1490.016CD44Negative/Positive\< 0.0016.4962.858--14.767\< 0.001Twist1Negative/Positive\< 0.0013.9511.673--9.3310.002KiSS-1Negative/Positive\< 0.0010.2710.110--0.6660.004^a^Subserosa: The tumor has grown through the mucosa and into the subserosa; Visceral peritoneum: The tumor has grown into the surface of the visceral peritoneum, which means it has grown through all layers of the colon, or the tumor has grown into or has attached to other organs or structures

Survival analysis {#Sec11}
-----------------

As shown in Fig. [2a](#Fig2){ref-type="fig"}, univariate OS analysis indicated that the OS time of MACC1+ (47.8 ± 12.5 months) for patients with CAC was significantly shorter than that of MACC1- for patients (62.0 ± 9.6 months; log-rank = 61.757, *P* \< 0.001). As shown in Fig. [2b](#Fig2){ref-type="fig"}, the univariate OS time of CD44+ (46.8 ± 12.9 months) was significantly lower than in CD44- patients (61.2 ± 8.9 months; log-rank = 54.938, *P* \< 0.001). As shown in Fig. [2c](#Fig2){ref-type="fig"}, the univariate OS time of Twist1+ patients (49.7 ± 13.0 months) was significantly lower than in Twist1- patients (59.7 ± 11.5 months; log-rank = 24.306, *P* \< 0.001). As shown in Fig. [2d](#Fig2){ref-type="fig"}, the univariate OS time of KiSS-1+ patients (64.7 ± 4.9 months) was significantly greater than that of KiSS-1- patients (45.7 ± 11.6 months; log-rank = 115.258, *P* \< 0.001). As shown in Fig. [2e](#Fig2){ref-type="fig"}, the univariate OS time of the combination of KiSS-1 negative expression and MACC1+, CD44+, and Twist1+ positive expression patients was significantly lower than that in KiSS-1 positive expression and MACC1-, CD44-, and Twist1- (log-rank = 84.625, *P* \< 0.001). The univariate OS time was also significantly closely associated with the following other clinicopathological characteristics, invasion (*P* = 0.002, log-rank = 14.868; Fig. [2f](#Fig2){ref-type="fig"}), LNM stages (*P* \< 0.001, log-rank = 325.068; Fig. [2g](#Fig2){ref-type="fig"}), and TNM stages (*P* \< 0.001, log-rank = 152.179; Fig. [2h](#Fig2){ref-type="fig"}) (Table [5](#Tab5){ref-type="table"}).Fig. 2Kaplan-Meier analysis curve of the survival rate of patients with CAC. The y-axis means the percentage of patients; the x-axis means their survival in months. **a**: OS analysis of all patients in relation to MACC1 (log-rank = 61.757, *P* \< 0.001); **b**: OS analysis of all patients in relation to CD44 expression (log-rank = 54.938, *P* \< 0.001); **c**: OS analysis of all patients in relation to Twist1 expression (log-rank = 24.306, *P* \< 0.001); **d**: OS analysis of all patients in relation to KiSS-1 expression (log-rank = 115.258, *P* \< 0.001). In **(a)**, (**b)**, (**c)** and (**d)** analyses, the green line represents patients with positive MACC1, or CD44, or Twist1 or KiSS-1; the blue line representing the negative MACC1, or CD44, or Twist1 or KiSS-1 group. E: OS survival of all patients in relation to the combination of KiSS-1, MACC1, CD44, and Twist1 expression (log-rank = 84.625, *P* \< 0.001). The green line represents negative KiSS-1 and positive MACC1, CD44, Twist1 and the blue line represents positive KiSS-1 and negative MACC1, CD44, Twist1. The brown line represents other positive or negative proteins. F: OS survival of all patients in relation to tumor invasion depth (log-rank = 14.868, *P* = 0.002); G: OS survival of all patients in relation to LNM stages (log-rank = 325.068, *P* \< 0.001); H: OS survival of all patients in relation to TNM stages (log-rank = 152.179, *P* \< 0.001)Table 5Results of univariate analyses of overall survival (OS) timeVariablenMean OS (months)Log-rank*P* valueMACC161.757\< 0.001 Negative8262.0 ± 9.6 Positive13047.8 ± 12.5CD4454.938\< 0.001 Negative9661.2 ± 8.9 Positive11646.8 ± 12.9Twist124.306\< 0.001 Negative7659.7 ± 11.5 Positive13649.7 ± 13.0KiSS-1115.258\< 0.001 Negative12745.7 ± 11.6 Positive8564.7 ± 4.9Gender0.0700.792 Male14254.0 ± 12.4 Female7052.0 ± 15.2Ages (year)0.2060.650 ≤ 6013454.3 ± 12.7 \> 607851.7 ± 14.4Size (cm)5.8870.053 ≤ 2.03355.0 ± 13.4 \> 2.0, ≤5.011051.0 ± 12.7 \> 5.06956.2 ± 13.9Location7.5030.057 Ascending4254.3 ± 14.0 Transverse6451.4 ± 13.4 Descending3352.3 ± 13.3 Sigmoid7354.9 ± 13.0Type3.7810.286 Ulcerative6555.3 ± 13.0 Infiltrating4651.8 ± 13.4 Polypoid6852.6 ± 14.0 Colloid3353.2 ± 12.7Invasion14.8680.002 Submucosa3660.2 ± 9.9 Muscularis6452.1 ± 14.7 Subserosa10152.7 ± 12.5 Visceral peritoneum1143.2 ± 14.4Grade3.5440.170 Well3256.1 ± 14.1 Moderate13553.7 ± 13.0 Poor4550.1 ± 13.5LNM stages325.068\< 0.001 N013660.6 ± 8.8 N17041.5 ± 9.1 N2626.3 ± 3.6TNM stage152.179\< 0.001 I6962.7 ± 7.4 II6758.4 ± 9.7 III7940.3 ± 9.7

Multivariate analysis suggested that MACC1, CD44, Twist1, and KiSS-1 expression, LNM stages, and TNM stages should be considered independent predictors affecting patient survival (Table [6](#Tab6){ref-type="table"}).Table 6Results of multivariate analyses of overall survival (OS) timeVariableBSE*P*RR95% CIMACC11.0700.198\< 0.0012.9171.978--4.301CD440.5120.1760.0041.6691.183--2.357Twist10.3480.1760.0481.4171.003--2.000KiSS-1−1.3680.201\< 0.0010.2550.172--0.377LNM stages0.8010.3680.0292.2291.084--4.581TNM stages0.6300.2600.0151.8771.127--3.124

Discussion {#Sec12}
==========

Colon cancer is a common malignant tumor of the digestive system. Its high heterogeneity makes it difficult to fully evaluate the comprehensiveness and effectiveness of any biomarker. Previous studies have demonstrated that MACC1 can promote tumor cell proliferation and migration \[[@CR3], [@CR4]\]. In this study, our findings indicated that positive expression of MACC1 in CAC was positively correlated with invasion and tumor differentiation and LNM and TNM stages. Positive expression of MACC1 was found to be significantly closely associated with lower OS time when compared with MACC1 negative. These findings demonstrated that MACC1 was considered an effective biomarker for invasion and metastasis, as well as a predictor for prognosis \[[@CR3]--[@CR8], [@CR27], [@CR28]\].

CD44 was initially considered an adhesion molecule capable of regulating cell-ECM adhesion, invasion, and metastasis \[[@CR16], [@CR17]\]. CD44 overexpression has been found to be correlated with tumorigenesis and to predict a poor response to anti-cancer therapy \[[@CR8], [@CR15]\]. The results recorded in this study also demonstrated that positive expression of CD44 in CAC was positively correlated with tumor differentiation, invasion, LNM stages, and TNM stages. CD44+ patients showed shorter OS times than CD44- patients. Several other studies have explored the metastatic and prognostic significance of CD44, and they produced similar results \[[@CR16], [@CR17]\]. These findings confirmed that CD44 may be an effective biomarker for predicting the invasion and metastasis of CAC and may predict prognosis.

EMT is believed to be involved in a series of fundamental biological behaviors, such as growth, motility, invasion, adhesion, metastasis, and recurrence. Twist1, which consists of two exons and one intron, is a pivotal transcriptional factor in EMT. The results of this study showed the expression of Twist1 in CAC to be positively associated with tumor differentiation, gross type, invasion, and LNM stages and TNM stages. Twist1+ patients showed significantly shorter OS than Twist1- patients. Because the infiltrating type of CAC tends to develop more rapidly than other types of CAC, which could suggest that Twist1 is a valuable biomarker for more aggressive CAC. In this way, our findings support the conclusion that Twist1 may be a reliable biomarker of CAC, particularly in predicting progression, metastasis, and prognosis.

KiSS-1 is considered a metastatic suppressor in many cancers \[[@CR11], [@CR25], [@CR26]\]. Results have demonstrated that the normal expression of KiSS-1 can suppress tumor cell growth, motility, and migration. The results of this study indicated a negative correlation between positive expression of KiSS-1 and tumor size, invasion, LNM stage, or TNM stage. KiSS-1+ patients were significantly associated with longer OS time when compared with KiSS-1- patients. These findings suggested that KiSS-1 should be considered as a potential predictor for progression and metastasis of CAC, as well as prognosis \[[@CR11], [@CR25], [@CR26], [@CR29]\].

In the current study, univariate analysis indicated that invasion, LNM, TNM stages, and expression of MACC1, CD44, Twist1, and KiSS-1 were significantly closely associated with duration of OS in patients with CAC. Multivariate OS analysis showed that LNM stages, TNM stages, positive expression of MACC1, CD44, Twist1, and KiSS-1 were independent predictors affecting patient survival. Multivariate metastasis logistic analysis showed expression of MACC1, CD44, Twist1, and KiSS-1, and invasion to be significantly closely associated with metastasis of CAC. These findings also demonstrated that MACC1, CD44, Twist1, and KiSS-1 should be considered to be useful biomarkers for predicting the invasion and metastasis of CAC, as well as a predictor for prognosis.

There were some differences between our results and previous findings. This may be related to the use of different biomarkers, different immunohistochemical methods, or even different patients (such as Wang W. et al., who reported that KiSS-1 expression was statistically significantly higher in colorectal cancer tissue than in corresponding adjacent normal mucosa \[[@CR30]\], Wu Q. et al. reported that CD44 expression was not associated with LNM in multivariate logistic regression analysis \[[@CR17]\], and Yusup A. et al. reported that Twist1 expression was not correlated with survival \[[@CR31]\]). However, we demonstrated that MACC1, CD44, Twist1, and KiSS-1 expression were associated with metastasis and prognosis of CAC. CSCs may indicate the initiation, progression, and metastasis of CAC. Their capacity for self-renewal, proliferation, and multiple forms of differentiation allow CSCs to induce EMT and so promote invasion and metastasis. CD44 is an adhesion molecule that can regulate cell-matrix adhesion. CD44 overexpression is beneficial to CAC progression and metastasis. During cancer progression, MACC1 overexpression should inhibit cancer cell apoptosis and promote cancer cell EMT via HGF/MET pathways \[[@CR32], [@CR33]\]. Twist1 overexpression could further promote the cancer cell EMT process through regulating E-cadherin, N-cadherin, and MMP expression \[[@CR21], [@CR34]\]. Thus, EMT could induce cancer cell motility, migration, and even metastasis. Aberrant expression of KiSS-1 could decrease or lower its ability to inhibit cancer cell invasion and metastasis \[[@CR11], [@CR25], [@CR26]\].

Conclusions {#Sec13}
===========

This study demonstrated that expression levels of MACC1, CD44, Twist1, and KiSS-1 are related to duration of OS among patients with CAC. In this way, MACC1, CD44, Twist1, and KiSS-1 could serve as valuable biomarkers in CAC and may be helpful for the metastasis and prognosis for CAC.
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